Dr. Sam Reynolds of Moffitt Cancer Center shares his perspective on the importance of research in advancing understanding and care for Erdheim-Chester Disease. Watch the video and help us recognize the researchers working toward better answers and outcomes for the ECD...
The ECD Global Alliance is accepting Letters of Intent for its 2026 Early Career Investigator Grant. Up to $60,000 USD will be awarded for a two-year research project focused on Erdheim-Chester Disease or related adult histiocytic disorders. International submissions...
A new study from Memorial Sloan Kettering Cancer Center highlights the promise of ulixertinib, a targeted therapy drug that blocks ERK, for treating certain forms of histiocytosis, including Erdheim-Chester Disease (ECD). Led by Dr. Eli Diamond, a member of the ECDGA...
The Erdheim-Chester Disease Global Alliance (ECDGA) is issuing a final call for Letters of Intent (LOIs) for the 2025 research grant. The application period closes tomorrow, so there is only one day left to submit. This annual funding opportunity supports innovative...
At the 2025 Erdhem-Chester Disease Medical Symposium in Barcelona, the ECDGA Junior Investigator Award went to Laura Eurelings of Erasmus University Medical Centre, Rotterdam. Her poster, “Anti-IL-6 Therapy in Rare Histiocytic Disorders: Erdheim-Chester and...
